Scinai Immunotherapeutics (SCNI) Gains from Investment Securities (2023 - 2026)

Scinai Immunotherapeutics has reported Gains from Investment Securities for 4 years, with the latest figure at $3.6 million in Q1 2026.

• Quarterly Gains from Investment Securities rose 129.74% year-over-year to $3.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.1 million (up 229.1% YoY) and the FY2025 annual result came in at -$3000.0, up 96.77% from the prior year.
• Gains from Investment Securities climbed to $3.6 million in Q1 2026 per SCNI's latest filing, from $1.6 million in the prior quarter.
• Over five years, Gains from Investment Securities peaked at $3.6 million in Q1 2026 and troughed at -$2.6 million in Q1 2023.
• A 4-year average of $112625.0 and a median of -$156000.0 in 2023 frame the typical range for Gains from Investment Securities.
• The sharpest annual moves came in 2024 and 2025: Gains from Investment Securities soared 96.26% in 2024, then surged 1721.88% in 2025.
• Over 4 years, Gains from Investment Securities stood at -$216000.0 in 2023, then soared by 101.39% to $3000.0 in 2024, then jumped by 51800.0% to $1.6 million in 2025, then jumped by 129.74% to $3.6 million in 2026.
• According to Business Quant data, Gains from Investment Securities over the past three periods registered $3.6 million, $1.6 million, and $3000.0 for Q1 2026, Q1 2025, and Q2 2024 respectively.